The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.
Treatment pathway is available on separate guidelines page.
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends upadacitinib as a treatment option for the treatment of active non-radiographic axial spondyloarthritis in line with NICE TA861
Upadacitinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA861.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
